137 related articles for article (PubMed ID: 31198461)
1. New Advances in Evaluation of Hearing in a Sample of Egyptian Children with β-Thalassemia Major.
Alzaree FA; Shehata MA; Atti MA; Elzaree GA; El-Kassas GM
Open Access Maced J Med Sci; 2019 May; 7(9):1494-1498. PubMed ID: 31198461
[TBL] [Abstract][Full Text] [Related]
2. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N
Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
[TBL] [Abstract][Full Text] [Related]
3. Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients.
Khan MA; Khan MA; Seedat AM; Khan M; Khuwaja SF; Kumar R; Usama SM; Fareed S
Cureus; 2019 Aug; 11(8):e5465. PubMed ID: 31641562
[TBL] [Abstract][Full Text] [Related]
4. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
5. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
Chao YH; Wu KH; Lin CY; Tsai MH; Peng CT; Wu HP; Lin CD
Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
[TBL] [Abstract][Full Text] [Related]
6. Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet.
Galhom DH; Talaat RM; Hanna D; Gad NH
Int J Pediatr Otorhinolaryngol; 2024 Feb; 177():111868. PubMed ID: 38252990
[TBL] [Abstract][Full Text] [Related]
7. Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions.
Md Daud MK; Mohamadl H; Haron A; Rahman NA
B-ENT; 2014; 10(1):53-8. PubMed ID: 24765829
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
9. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
10. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
Delehaye E; Capobianco S; Bertetto IB; Meloni F
Auris Nasus Larynx; 2008 Jun; 35(2):198-202. PubMed ID: 17869044
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
12. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
13. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
[TBL] [Abstract][Full Text] [Related]
14. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Abdelrazik N
Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
[TBL] [Abstract][Full Text] [Related]
15. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
Ambrosetti U; Dondè E; Piatti G; Cappellini MD
Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
[TBL] [Abstract][Full Text] [Related]
16. Long term audiological evaluation of beta-thalassemic patients.
Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
[TBL] [Abstract][Full Text] [Related]
17. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
Karimi M; Asadi-Pooya AA; Khademi B; Asadi-Pooya K; Yarmohammadi H
Acta Haematol; 2002; 108(2):79-83. PubMed ID: 12187025
[TBL] [Abstract][Full Text] [Related]
19. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
Soliman AT; Yassin MA; De Sanctis V
Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
[TBL] [Abstract][Full Text] [Related]
20. The Prevalence of Sensorineural Hearing Loss in β-thalassaemia patient treated with Desferrioxamine.
Kong MH; Goh BS; Hamidah A; Zarina AL
Med J Malaysia; 2014 Feb; 69(1):9-12. PubMed ID: 24814621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
